PACIRA BIOSCIENCES, INC. Asset Retirement Obligation, Accretion Expense
PACIRA BIOSCIENCES, INC. (PCRX) reported Asset Retirement Obligation, Accretion Expense of $100.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AssetRetirementObligationAccretionExpense · last filed 2021-03-01
- PACIRA BIOSCIENCES, INC. asset retirement obligation, accretion expense for the quarter ending 2019-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, accretion expense for the quarter ending 2019-09-30 was $100.00K.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, accretion expense for fiscal 2020 was $100.00K, a 50.00% decline from fiscal 2019.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, accretion expense for fiscal 2019 was $200.00K, a 100.00% increase from fiscal 2018.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, accretion expense for fiscal 2018 was $100.00K, a 0.00% change from fiscal 2017.
- PACIRA BIOSCIENCES, INC. asset retirement obligation, accretion expense for fiscal 2017 was $100.00K.
| Period end | Asset Retirement Obligation, Accretion Expense 3 month | Asset Retirement Obligation, Accretion Expense 6 month | Asset Retirement Obligation, Accretion Expense 9 month | Asset Retirement Obligation, Accretion Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $100.00K 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $100.00K derived: sum of 2 quarters · filed 2021-03-01 | $200.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $100.00K 10-Q · filed 2019-11-08 | $200.00K 10-Q · filed 2019-11-08 | ||
| 2018-12-31 | $100.00K 10-K · filed 2020-02-21 | |||
| 2017-12-31 | $100.00K 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |